Pharmafile Logo
Pharmafocus logo
Advanced Search

CSL

Showing 5 posts of 5 posts found.

clinical_trial_4

FDA approves CSL haemophilia A drug

May 26, 2016
Sales and Marketing CSL, afstyla, haemophilia a, treatment

CSL (ASX: CSL) has announced that the US Food and Drug Administration (FDA) has approved Afstyla (antihaemophilic factor [recombinant), single …

News
needles

CSL’s flu vaccine scores FDA approval

May 24, 2016
Manufacturing and Production, Research and Development, Sales and Marketing CSL, FDA, Vaccine, flu, four strain, four-strain, influenza, influenza a, influenza b, seqirus

Seqirus, a division of CSL, has announced that the US Food and Drug Administration (FDA) has approved Flucelvax Quadrivalent (influenza …

News
lab

EU approves Idelvion for haemophilia B treatment

May 13, 2016
Medical Communications, Research and Development CSL, EU, Idelvion, approval, haemophilia B

The European Commission has approved Idelvion, coagulation Factor IX (recombinant) for the treatment and prophylaxis of bleeding in patients with …

News

CSL completes $275m Novartis vaccines acquisition

August 3, 2015
Manufacturing and Production, Sales and Marketing CSL, Novartis, acquisitions, asset swap, vaccines

CSL Limited has finalised its transaction to acquire Novartis’s global influenza vaccine business for $275 million. The move means Novartis …

News

CSL vaccine plant cited in FDA letter

July 1, 2010
Manufacturing and Production CSL, GMP, P&G, manufacturing compliance

CSL Biotherapies has been sent a letter by the US Food and Drug Administration which indicates that vials of seasonal …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024